Market Research Report
Sustained Release Injectables to 2026
|Published by||Greystone Research Associates||Product code||672887|
Delivery time: 1-2 business days
|Sustained Release Injectables to 2026|
|Published: August 6, 2019||Content info:||
Currently approved sustained release injectables rely on a spectrum of branded formulation technologies to modulate the drug's release profile post-injection. Typically off-patent or generic drugs, they include drug therapies for almost a dozen major therapeutic segments, including neurological conditions, metabolic diseases, oncology, pain management and reproductive health. As the incidence and prevalence of chronic illnesses increases with the aging population, the attraction and interest in sustained release injectables will increase.